Page 77 - Diamicron MR MIG Cycle 2(20-21) Final

6 di ab e t es re s e ar ch and c lin i c a l p ra ct ic e 16 3 (20 20) 1 0815 4

Table 1 – Baseline characteristics.
Patients (N = 1214)
Demographic characteristics
Gender, n (%)
Male 665 (54.8)
Female 549 (45.2)
Age (years)
Mean (SD) 54.1 (10.5)
Age class (years), n (%)
<50 408 (33.6)
50 and 65 637 (52.5)
>65 169 (13.9)
Region and country, n (%)
Asia Pacific 860 (70.8)
Bangladesh 98 (8.1)
India 246 (20.3)
Indonesia 198 (16.3)
Malaysia 98 (8.1)
Pakistan 220 (18.1)
Middle East/North Africa 354 (29.2)
Egypt 193 (15.9)
Kuwait 14 (1.2)
Saudi Arabia 130 (10.7)
United Arab Emirates 17 (1.4)
Working status, n (%)
Active full-time worker 424 (34.9)
Active part-time worker 143 (11.8)
Non-active worker 200 (16.5)
Student 3 (0.2)
Retired 206 (17.0)
Other 221 (18.2)
Missing data 17 (1.4)
Physical activity, n (%)
Sedentary 427 (35.2)
Moderate 669 (55.1)
Intermediate 90 (7.4)
Intensive 9 (0.7)
Missing data 19 (1.6)
Medical history, n (%)*
Vascular disorders 437 (36.0)
Hypertension 435 (35.8)
Metabolism and nutrition disorders 374 (30.8)
Dyslipidaemia 350 (28.8)
Nervous system disorders 102 (8.4)
Diabetic neuropathy 85 (7.0)
Cardiac disorders 77 (6.3)
Myocardial infarction 28 (2.3)
Concomitant treatments, n (%)
Number of antidiabetic treatments
1 495 (40.8)
2 362 (29.8)
3 357 (29.4)
Cardiovascular therapies, n (%)
Statin or ezetimibe 413 (34.0)
ACEi or ARB 179 (14.7)
Beta-blocker 121 (10.0)
Antiplatelet agents 110 (9.1)
CCB 110 (9.1)
Diuretics 42 (3.5)
(continued on next page)